ArticleNPJ precision oncology2017
Towards personalized tumor markers.
Article in NPJ precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Rethinking biomarkers in psychiatry: from etiological uncertainty to actionable prediction.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study.Research and practice in thrombosis and haemostasis · 2025Article
- Computational Chemistry Study of pH-Responsive Fluorescent Probes and Development of Supporting Software.Molecules (Basel, Switzerland) · 2025Article
- A new weapon: the application of tumor vaccines based on extracellular exosomal heat shock proteins in immunotherapy.Frontiers in immunology · 2025Review
- Small-Molecule Fluorescent Probes for Detecting Several Abnormally Expressed Substances in Tumors.Micromachines · 2022Review
- Article
- Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden.F1000Research · 2021Article
- GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.BMC cancer · 2020Article
- Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden.F1000Research · 2020Article
- Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study.Journal of extracellular vesicles · 2020Article
- High Tiam1 expression predicts positive lymphatic metastasis and worse survival in patients with malignant solid tumors: a systematic review and meta-analysis.OncoTargets and therapy · 2019Review
- The 9th Santorini Conference: Systems Medicine, Personalised Health and Therapy. "The Odyssey from Hope to Practice", Santorini, Greece, 30 September⁻3 October 2018.Journal of personalized medicine · 2018Article
- Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.NPJ precision oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer biomarker discovery pipeline is progressing slowly. The difficulties of finding novel and effective biomarkers for diagnosis and management of cancer patients are well-known. We speculate that it is unlikely to discover new serological biomarkers characterized by high sensitivity and specificity. This projection is supported by recent findings that cancers are genetically highly heterogeneous. Here, we propose a new way of improving the landscape of cancer biomarker research. There are currently hundreds, if not thousands, of described biomarkers which perform at high specificity (> 90%), but at relatively low sensitivity (< 30%). We call these "rare tumor markers." Borrowing from the principles of precision medicine, we advocate that among these low sensitivity markers, some may be useful to specific patients. We suggest screening new patients for hundreds to thousands of cancer biomarkers to identify a few that are informative, and then use them clinically. This is similar to what we currently do with genomics to identify personalized therapies. We further suggest that this approach may explain as to why some biomarkers are elevated in only a small group of patients. It is likely that these differences in expression are linked to specific genomic alterations, which could then be found with genomic sequencing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.